Quantitative analysis of plasma DNA in colorectal cancer patients - A novel prognostic tool

被引:77
作者
Frattini, Milo
Gallino, Gianfrancesco
Signoroni, Stefano
Balestra, Debora
Battaglia, Luigi
Sozzi, Gabriella
Leo, Ermanno
Pilotti, Silvana
Pierotti, Marco A. [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, I-20133 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Unit Expt Mol Pathol, Dept Pathol, I-20133 Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Colorectal Surg Unit, Milan, Italy
[4] Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Milan, Italy
[5] FIRC, Inst Mol Oncol, Milan, Italy
来源
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM IV | 2006年 / 1075卷
关键词
colorectal cancer (CRC); carcinoembryonic antigen (CEA);
D O I
10.1196/annals.1368.025
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extracellular DNA in the plasma or serum of cancer patients has been recently proposed as a source of analyzable cancer-related gene sequences (qualitative approach). Furthermore, patients with different tumor types show high levels of cell-free circulating DNA both in plasma and serum (quantitative approach) at the time of surgery. Our aim was to verify whether the level of cell-free DNA in plasma might help in detecting recurrences during follow-up of colorectal cancer (CRC) patients. We studied 70 patients undergoing surgery for primary CRC. Plasma samples were obtained at the time of surgery and during follow-up. The cell-free circulating DNA in plasma was quantified by the Dipstick Kit method. At the time of surgery, in all patients, cell-free DNA levels in plasma were about 25 times higher in comparison with 20 healthy donors. In contrast, the carcinoembryonic antigen (CEA) value of this cohort of patients was altered in only about 37% of cases. During follow-up, cell-free DNA levels decreased progressively in tumor-free patients, while it increased in those developing recurrences or metastases.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 8 条
[1]   Reproducibility of a serniquantitative measurement of circulating DNA in plasma from neoplastic patients [J].
Frattini, M ;
Balestra, D ;
Verderio, P ;
Gallino, G ;
Leo, E ;
Sozzi, G ;
Pierotti, MA ;
Daidone, MG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3163-3164
[2]  
Gion M, 1996, ANTICANCER RES, V16, P2279
[3]   Genetic pathways in colorectal and other cancers [J].
Ilyas, M ;
Straub, J ;
Tomlinson, IPM ;
Bodmer, WF .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (03) :335-351
[4]  
Johnson PJ, 2002, CLIN CHEM, V48, P1186
[5]   Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker [J].
Linder, S ;
Havelka, AM ;
Ueno, T ;
Shoshan, MC .
CANCER LETTERS, 2004, 214 (01) :1-9
[6]  
Sozzi G, 2001, CANCER RES, V61, P4675
[7]   Cell-free DNA: measurement in various carcinomas and establishment of normal reference range [J].
Wu, TL ;
Zhang, D ;
Chia, JH ;
Tsao, KC ;
Sun, CF ;
Wu, JT .
CLINICA CHIMICA ACTA, 2002, 321 (1-2) :77-87
[8]   Circulating DNA: a new diagnostic gold mine? [J].
Ziegler, A ;
Zangemeister-Wittke, U ;
Stahel, RA .
CANCER TREATMENT REVIEWS, 2002, 28 (05) :255-271